China’s FDA Accepts JHL Biotech’s Clinical Trial Application for Rituximab Biosimilar in NHL

Published date06 April 2017
Law FirmGoodwin
Subject MatterChina,Clinical Trials,Biologics,China FDA,Pharmaceutical Industry

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT